Sign in

    Rajiv Prasad

    Research Analyst at William Blair

    Raju Prasad, Ph.D., was Partner and Senior Biotechnology Analyst at William Blair, specializing in cell therapy, gene therapy, and gene editing, where he led the firm’s coverage initiation in these sectors and analyzed a broad range of companies from small to large cap. His coverage included notable biotech firms such as Boundless Bio and Rocket Pharmaceuticals, supported by analytical contributions in earnings calls and sector research. Prasad joined William Blair in 2014 and advanced to Partner by 2021 before leaving in 2023 to become CFO at CRISPR Therapeutics, following an academic research background and experience as a consultant for the U.S. Environmental Protection Agency. He holds a B.A. from Rutgers, an M.S. from the University of Delaware, and a Ph.D. from the University of North Carolina, and has been recognized for leading research initiatives and authoring a book on medical innovation.

    Rajiv Prasad's questions to Boundless Bio (BOLD) leadership

    Rajiv Prasad's questions to Boundless Bio (BOLD) leadership • Q3 2019

    Question

    Rajiv Prasad of William Blair asked for a comparison of the current Pompe construct versus the previous one, particularly regarding potency and biodistribution, and questioned if the muscle-directed approach was also being applied to the DMD program.

    Answer

    CEO Matt Patterson explained that the only change to the Pompe product was the promoter, which was fine-tuned to optimize expression levels, and that the preclinical data is very strong. He emphasized the approach is focused on muscle expression. He clarified that the DMD program utilizes a different scientific approach, vectorized exon skipping, which involves a different promoter situation than the direct protein expression used in Pompe.

    Ask Fintool Equity Research AI